The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

8485088474098459390428079b-476a-4f2d-ab2e-88d1eabba7c151ac6f34-99db-47e9-973e-7040b2df72934d480b65-e669-4e35-bdae-2fd4e559740dARGS_News_2015_9_1_General_Releases.pdfARGS_News_2015_8_24_General_Releases.pdfARGS_News_2015_8_12_General_Releases.pdf1740816802288431232015-9-1T8:30:0-4:02015-8-24T8:30:0-4:02015-8-12T16:5:0-4:0929638928549927443General ReleasesGeneral ReleasesGeneral ReleasesThe Company Will Share Perspectives on Clinical Development and Manufacturing of Individualized Immunotherapies.Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV InfectionArgos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights111111111201520152015No Error0

Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015
Read more

Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection
Read more

Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC